Genetic Analysis: Q3 2025 sales rose 2.9% year-over-year, with new product launches and US expansion driving growth

About this update from Genetic Analysis As

Sales revenue grew 2.9% year-over-year in Q3 2025, with gross margin impacted by new US import duties. The company advanced its IBD Dx marker project and launched the GA-mapⓇ MHI GutHealth test in the US and globally, supporting a positive outlook for continued growth.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genetic Analysis As